Peptide Synthesis Market

Peptide Synthesis Market

Peptide Synthesis Market to Reach US$ 4.2 bn by 2032, driven by steep rise in the adoption of peptides in the pharmaceutical and consumer healthcare industries: Global Insight Services

New York, July 2023: According to a new research study by Global Insight Services (GIS), the global Peptide Synthesis Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 4.2 bn by 2032.

Peptides are a unique class of highly active and specific pharmaceutical compounds, molecularly poised between small molecules and proteins, yet biochemically and therapeutically diverse from both. The advantages of peptides, such as relative ease of synthesis, ready availability, and low toxicity, increased their applications in the pharmaceutical, nutritional, and cosmetic industries, resulting in high demand for rapid advancements in the technologies to enhance their synthesis..

Request Sample Pages of this Research Report:

Peptide Synthesis Market: Key Trends and Drivers

The market for peptides has experienced significant growth due to their widespread adoption in the pharmaceutical and consumer healthcare industries. Peptides are being increasingly utilized in the treatment of various lifestyle disorders, including cancers, diabetes, and obesity. The rising prevalence of these metabolic and lifestyle disorders has created a favorable environment for the application of peptide therapeutics in the fields of oncology and metabolic disorders. According to data published by the International Diabetes Federation in 2021, there were 537 million adults (20-79 years) globally living with diabetes, which accounted for approximately 1 in 10 individuals. Additionally, 541 million adults were identified as having Impaired Glucose Tolerance (IGT), putting them at a high risk of developing type 2 diabetes. Peptide therapies like Glucagon-like peptide-1amide have gained popularity in pancreatic therapy as they stimulate insulin secretion postprandially. Consequently, the increasing number of diabetic patients is expected to drive the demand for peptide drugs and contribute to market growth in the foreseeable future.

The peptide synthesis market has also witnessed significant expansion due to increased research activities, novel product approvals, and enhanced funding for research and development. Furthermore, advancements in peptide synthesizers have provided additional advantages, further fueling market growth. An example of recent progress in this field is ISSAR Pharma’s announcement in April 2021 regarding the licensing of their peptide-based New Chemical Entities (NCEs), which have reached the pre-investigational new drug (IND) filing stage and obtained a United States patent. These notable developments in peptide drugs are expected to create a surge in market demand and drive the overall growth of the industry.

Peptide Synthesis Market: Restraints & Challenges

The peptide synthesis market faces several restraints that can hinder its growth and development. Firstly, the high cost of peptide synthesis, including equipment, reagents, and skilled labor, presents a significant barrier for entry and limits the accessibility of peptide synthesis technologies. Additionally, the complexity and time-consuming nature of peptide synthesis processes pose challenges in terms of scalability and efficient production, limiting the ability to meet the growing demand for peptides in various fields such as pharmaceuticals and biotechnology. Furthermore, regulatory constraints and safety concerns related to the use of peptides, especially in therapeutic applications, impose strict guidelines and approval processes, leading to delays and additional costs. These restraints collectively impede the expansion and advancement of the peptide synthesis market.

Peptide Synthesis Market Report Findings

The equipment segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

Based on the product, the global market for peptide synthesis is divided into equipment, reagents & consumables, and others. Out of these equipment segment accounted for substantial market share in the year 2022.. The development of innovative peptide synthesis equipment has greatly contributed to the rapid growth of this segment in the global market. For instance, in February 2017, researchers at MIT introduced a new piece of equipment that enables faster peptide synthesis compared to existing options. This automated machine can create links between amino acids in just approximately 37 seconds, allowing for the production of large quantities of customized peptides in a shorter timeframe. On the other hand, reagents and consumables have generated the highest revenue among other peptide synthesis products. This is mainly due to their regular use in peptide synthesis protocols. Furthermore, recent advancements in peptide coupling reagents are expected to further drive market growth in the upcoming years.

The Liquid Phase Peptide Synthesis (LPPS) segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

By technology, the industry is bifurcated into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid & Recombinant Technology. Liquid-phase peptide synthesis has dominated the global market throughout the projected period, while solid-phase peptide synthesis has exhibited the fastest growth from 2022 to 2032. The integration of automation and advancements in both liquid and solid-phase peptide synthesis has significantly contributed to cost reduction in peptide synthesis, driving its adoption worldwide and leading to increased global revenue. Traditional studies suggest that solid-phase peptide synthesis is a suitable approach for GMP manufacturing and API process development, particularly for cost-effective synthesis of long peptide sequences (more than 10 amino acids) in smaller volumes. However, purification costs during solid-phase peptide synthesis can increase manufacturing costs at any production scale. On the other hand, liquid-phase peptide synthesis is commonly used for developing shorter peptide sequences and larger volumes. Hybrid approaches are employed for synthesizing long sequences in large volumes.

The therapeutics segment is likely to hold a dominant Peptide Synthesis Market share and grow at a substantial CAGR during the forecast period.

Based on application, the industry is categorized into therapeutics, diagnosis, and research. The therapeutics segment, which includes various medical areas such as cancer, metabolic disorders, cardiovascular disorders, respiratory conditions, gastrointestinal disorders, infectious diseases, pain management, dermatology, central nervous system disorders, renal conditions, and others, was the leading revenue generator in the year 2022. This segment is anticipated to maintain its dominance throughout the forecast period.

On the other hand, the diagnosis segment is projected to experience the fastest growth from 2019 to 2026. The use of synthesized peptides in cancer treatment has significantly contributed to the revenue generated by the therapeutics segment, making it a major contributor in this market. Furthermore, within the therapeutics segment, the metabolic disorders segment is expected to exhibit the highest growth rate over the forecast period. This growth can be attributed to the presence of a robust pipeline and a substantial number of peptide candidates for treating type II diabetes. The discovery of novel peptides that play a crucial role in metabolic regulation is anticipated to provide valuable insights for the development of effective therapeutic approaches.

The Pharmaceutical & Biotechnology Companies segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

Based on end-user, the Peptide Synthesis market is divided into Pharmaceutical & Biotechnology Companies, Contract Development and Manufacturing Organization (CDMO), and Academic and Research Institutes. Among these, pharmaceutical and biotechnology companies are accounted for significant market share in 2022. This is owing to peptide therapies are gaining popularity in the pharmaceutical and biotechnology industries due to their cost-effectiveness, efficiency, and lower toxicity. The market for peptide synthesis is being driven by rapid advancements in peptide synthesizers and a robust pipeline of peptide therapeutics. In a 2022 article titled “Advances in oral peptide drug nanoparticles for diabetes mellitus treatment” published in Science Direct, it was highlighted that oral administration of peptide medications holds promise for treating diabetes mellitus. This approach is considered advantageous over traditional parenteral administration methods due to its simplicity and high patient compliance.

The growth of the market is further fueled by product launches, mergers, acquisitions, and the presence of competitors. An example of this is the world’s first “Peptide In A Pill” launched by Novo Nordisk India in January 2022. The peptide, Semaglutide, belongs to the GLP-1 receptor analog (GLP-1 RA) drug class and is used for managing type 2 diabetes. These developments are anticipated to drive the expansion of the pharmaceutical and biotechnology end-user segment in the peptide synthesis market.

The North America region is estimated to exhibit the highest growth rate during the Peptide Synthesis Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is projected to maintain its dominant position in the peptide synthesis market throughout the forecast period. This dominance can be attributed to the presence of advanced healthcare infrastructure and substantial investments by key players in North America. These investments aim to develop new peptide synthesis technologies, further fueling market expansion. For instance, in 2020, the United States Food and Drug Administration (US FDA) approved Imcivree (setmelanotide), a peptide derived from pro-opiomelanocortin, for chronic weight management in patients aged six years and older with obesity caused by rare genetic conditions. The US FDA’s accelerated drug approval initiative also plays a significant role in driving market growth in the region. These factors collectively contribute to North America’s outstanding market share in the global peptide synthesis market.

Moreover, increasing prevalence of obesity caused by sedentary lifestyles, poor dietary habits, and lack of physical activity, leading to various chronic diseases like diabetes in the United States. Effective treatment options are necessary to address these health concerns. For example, according to the International Diabetic Federation’s 2021 report, the North America Caribbean (NAC) region had an estimated 51 million adults aged 20-29 years living with diabetes, representing a regional prevalence of 14.6%. Additionally, this region has the second highest number of children and adolescents with type 1 diabetes, reaching 193,000 cases. The high prevalence of diabetes is expected to persist, resulting in a higher demand for peptide therapeutics and driving market growth in this region.

Have a question for our analyst:

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Peptide Synthesis market include Bachem Holding AG, Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation, Kaneka Corporation, Biotage AB, Syngene International Ltd. , Mesa Laboratories inc. , CEM Corporation and ProteoGenix, among others.

Recent Developments in the Peptide Synthesis Market:

  • In June 2022, Evonik launched a new peptide to boost the productivity of cell-culture-based biopharmaceuticals. cQrex AC is a chemically defined and highly soluble source of L-cystine that enables a sufficient supply of this key amino acid to cells.
  • In May 2022, the United States Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Peptide Synthesis Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Peptide Synthesis Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Peptide Synthesis market in terms of revenue ($Million)
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Peptide Synthesis Market industry.
  • A thorough analysis of market trends and restraints is provided
  • By region as well as country market analysis is also presented in this report
  • Analytical depiction of the Peptide Synthesis Market along with the current trends and future estimations to depict imminent investment pockets. The overall Peptide Synthesis Market Industry opportunity is examined by understanding profitable trends to gain a stronger foothold
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Peptide Synthesis Market are also analyzed.

Global Peptide Synthesis Market Segmentation

By Product

  • Equipment
  • Reagents & Consumables
  • Others

By Technology

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid & Recombinant Technology

By Application

  • Therapeutics
  • Diagnosis
  • Research

By End-user

  • Pharmaceutical & Biotechnology Companies
  • Contract Development & Manufacturing Organization/Contract Research Organization
  • Academic & Research Institutes

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Bachem Holding AG
  • Thermo Fisher Scientific
  • Merck KGaA
  • GenScript Biotech Corporation
  • Kaneka Corporation
  • Biotage AB
  • Syngene International Ltd.
  • Mesa Laboratories inc.
  • CEM Corporation
  • ProteoGenix